For instance, DNA methylation panels including several gene promoters (RASSF1A, CRIPTO, HOXA9, MGMT, and SCGB3A1) were reported as useful for subtyping and prognostication of disease, including in tissues and liquid biopsies [24, 53, 54], and demethylating agents demonstrated anti‐tumor effects in pre‐clinical studies [55, 56, 57, 58]. The gene discussed is CRIPTO; the disease is neoplasm.